TD 214
Alternative Names: PanCytoVir™ related analog - TrippBio; Probenecid related analog - TrippBio; TD-214Latest Information Update: 28 Aug 2023
At a glance
- Originator University of Georgia
- Developer TrippBio
- Class Antivirals; Sulfonamides; Uricosurics
- Mechanism of Action Organic anion transport protein 3 inhibitors; Urate transporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dengue; Influenza virus infections; Respiratory syncytial virus infections; Zika virus infection
Most Recent Events
- 24 Jul 2023 TrippBio in-licenses TD 213 from University of Georgia Research Foundation
- 17 Jul 2023 Preclinical trials in Dengue in USA (unspecified route) prior to July 2023 (TrippBio pipeline, July 2023)
- 17 Jul 2023 Preclinical trials in Influenza virus infections in USA (unspecified route) prior to July 2023 (TrippBio pipeline, July 2023)